Definium Therapeutics, Inc (DFTX) insider trading
Every open-market stock purchase and sale by Definium Therapeutics, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Robert Barrow (CEO) and 4 others sold $3M in the last 90 days.
- No open-market insider buys on record.
Last 12 months: insiders bought $0 (0 buys) and sold $6.4M (14 sales). Last close $36.00 on Oct 22, 2026.
Recent DFTX insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Sep 25, 2026 | Robert Barrow (CEO) | Sold | $1.2M |
| Sep 25, 2026 | Mark Sullivan (C-suite exec) | Sold | $514K |
| Sep 25, 2026 | Daniel Karlin (C-suite exec) | Sold | $397K |
| Sep 25, 2026 | Brandi Roberts (CFO) | Sold | $123K |
| Sep 25, 2026 | Matthew T. Wiley (C-suite exec) | Sold | $113K |
| Sep 18, 2026 | Andreas Krebs (Insider) | Bought (not open market) | $57.9K |
| Sep 18, 2026 | Carol A Vallone (Insider) | Bought (not open market) | $38.6K |
| Sep 18, 2026 | Carol A Vallone (Insider) | Bought (not open market) | — |
| Sep 18, 2026 | Andreas Krebs (Insider) | Bought (not open market) | — |
| Sep 14, 2026 | Matthew T. Wiley (C-suite exec) | Bought (not open market) | — |
| Sep 14, 2026 | Daniel Karlin (C-suite exec) | Bought (not open market) | — |
| Sep 14, 2026 | Mark Sullivan (C-suite exec) | Bought (not open market) | — |
| Sep 14, 2026 | Brandi Roberts (CFO) | Bought (not open market) | — |
| Sep 14, 2026 | Robert Barrow (CEO) | Bought (not open market) | — |
| Sep 3, 2026 | Robert Barrow (CEO) | Sold | $722K |
| Sep 2, 2026 | Robert Barrow (CEO) | Bought (not open market) | — |
| Aug 12, 2026 | Robert Barrow (CEO) | Bought (not open market) | — |
| Aug 12, 2026 | Daniel Karlin (C-suite exec) | Bought (not open market) | — |
| Aug 12, 2026 | Mark Sullivan (C-suite exec) | Bought (not open market) | — |
| Aug 12, 2026 | Matthew T. Wiley (C-suite exec) | Bought (not open market) | — |
| Aug 12, 2026 | Brandi Roberts (CFO) | Bought (not open market) | — |
| Jun 25, 2026 | Robert Barrow (CEO) | Sold | $1.3M |
| Jun 25, 2026 | Mark Sullivan (C-suite exec) | Sold | $586K |
| Jun 25, 2026 | Daniel Karlin (C-suite exec) | Sold | $452K |
| Jun 25, 2026 | Brandi Roberts (CFO) | Sold | $136K |
Who's trading DFTX
- Matthew T. Wiley, C-suite exec: sold $242K (2 sales), last Sep 25, 2026
- Robert Barrow, CEO: sold $3.6M (4 sales), last Sep 25, 2026
- Daniel Karlin, C-suite exec: sold $997K (3 sales), last Sep 25, 2026
- Brandi Roberts, CFO: sold $259K (2 sales), last Sep 25, 2026
- Mark Sullivan, C-suite exec: sold $1.3M (3 sales), last Sep 25, 2026
- Andreas Krebs, Insider: other filings, last Sep 18, 2026
- Carol A Vallone, Insider: other filings, last Sep 18, 2026
- Roger Adsett, Insider: other filings, last Jun 11, 2026
- Suzanne Louise Bruhn, Insider: other filings, last Jun 11, 2026
- Roger Crystal, Insider: other filings, last Jun 11, 2026
- David W Gryska, Insider: other filings, last Jun 11, 2026
Get free alerts when an insider at Definium Therapeutics, Inc files a new trade →